Subtype
Benign Peripheral Nervous System Neoplasm
CI-CAN-00000532Explore in graph →
Non-malignant21 active trials2 evidence items
- NCIt
- C213862
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000532Explore in graph →
Clinical trials
61 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00924196 | Natural History Study of Patients With Neurofibromatosis Type I | active not recruiting | — | 259 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00314119 | Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 | completed | — | 17 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01362803 | AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | active not recruiting | Phase 1 / Phase 2 | 99 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06175637 | Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs(PEDIA) | active not recruiting | — | 409 | AstraZenecaINDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07298083 | DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins | recruiting | — | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06515860 | Neurofibromatosis Type 1 Tumor Early Detection Study(NF1-TED) | enrolling by invitation | — | 1,000 | David MillerOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT02402244 | Project: Every Child for Younger Patients With Cancer | recruiting | — | 75,000 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT06360406 | Real-World Treatment Study of Koselugo (Selumetinib) | recruiting | — | 200 | AstraZenecaINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06502171 | Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas(NF113) | recruiting | Phase 1 | 30 | Girish Dhall, MDOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04590235 | A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) | active not recruiting | Phase 1 | 32 | AstraZenecaINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06880991 | Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study | recruiting | — | 110 | National Cancer Institute (NCI)NIH | 1 | Aug 14, 2026 | clinicaltrials |
| NCT03962543 | MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas(ReNeu) | active not recruiting | Phase 2 | 114 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05891847 | Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia | terminated | — | 150 | AstraZenecaINDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06104488 | A Study of Avutometinib for People With Solid Tumor Cancers | active not recruiting | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06188741 | Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1(NF114) | recruiting | Phase 2 | 200 | University of Alabama at BirminghamOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07407803 | Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas | recruiting | Phase 3 | 177 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT03583528 | DOTATOC PET/CT for Imaging NET Patients | active not recruiting | — | 800 | British Columbia Cancer AgencyOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07102394 | Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 | recruiting | Phase 1 | 10 | Johns Hopkins UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03363217 | Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. | active not recruiting | Phase 2 | 114 | St. Justine's HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06300502 | Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs) | enrolling by invitation | Phase 1 | 15 | Massachusetts General HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06159166 | Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).(Mirda) | recruiting | Phase 1 / Phase 2 | 24 | Johns Hopkins UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04040088 | An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors | active not recruiting | Early Phase 1 | 20 | Mayo ClinicOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04924608 | Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas(KOMET) | active not recruiting | Phase 3 | 145 | AstraZenecaINDUSTRY | 13 | Mar 23, 2026 | clinicaltrials |
| NCT05005845 | NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | completed | Phase 2 | 199 | NFlection Therapeutics, Inc.INDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06322342 | Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent | completed | Phase 2 | 18 | Reveal Pharmaceuticals Inc.INDUSTRY | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06961565 | PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas | recruiting | Phase 1 | 56 | Pasithea Therapeutics Corp.INDUSTRY | 3 | Dec 4, 2025 | clinicaltrials |
| NCT05581511 | Natural History Study of Cutaneous Neurofibromas in People With NF1(cNF Natural Hx) | active not recruiting | — | 500 | Johns Hopkins UniversityOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT05192980 | SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours(BIOPORTAL) | recruiting | N/A | 600 | Institut CurieOTHER | 4 | Jul 22, 2025 | clinicaltrials |
| NCT07024394 | Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1 | not yet recruiting | Phase 1 / Phase 2 | 65 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Jun 17, 2025 | clinicaltrials |
| NCT03231306 | Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas(NF108-BINI) | completed | Phase 2 | 45 | University of Alabama at BirminghamOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT05913037 | FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas | active not recruiting | Phase 3 | 167 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT04730583 | Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas | completed | Phase 1 | 34 | Massachusetts General HospitalOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT04954001 | Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 | active not recruiting | Phase 1 / Phase 2 | 160 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 3 | Nov 12, 2024 | clinicaltrials |
| NCT03531814 | Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials | completed | N/A | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2024 | clinicaltrials |
| NCT06296732 | Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification(ANLAP-R) | recruiting | — | 200 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT05438290 | DPCP to Treat Cutaneous Neurofibromas Associated With NF1 | completed | Phase 1 | 17 | Nicholas GulatiOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT06379230 | A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE) | unknown | — | 2,000 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT03741101 | Treatment of NF1-related Plexiform Neurofibroma With Trametinib(plexifpc) | unknown | Phase 2 | 15 | Region SkaneOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT03326388 | Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours(INSPECT) | completed | Phase 1 / Phase 2 | 14 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT05199376 | Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1(CryoNF1) | recruiting | N/A | 30 | Centre Leon BerardOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT02839720 | Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04435665 | NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | completed | Phase 2 | 48 | NFlection Therapeutics, Inc.INDUSTRY | 1 | Aug 9, 2022 | clinicaltrials |
| NCT01800032 | PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1) | completed | — | 30 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 12, 2021 | clinicaltrials |
| NCT03820778 | Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 | active not recruiting | N/A | 10 | Children's National Research InstituteOTHER | 1 | Mar 2, 2021 | clinicaltrials |
| NCT03688568 | Study of Imatinib in Children With Neurofibromatosis and Airway Tumors | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 1 | Feb 12, 2021 | clinicaltrials |
| NCT03027401 | Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics | withdrawn | — | 0 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2020 | clinicaltrials |
| NCT01347307 | Stereotactic Body Radiotherapy for Spine Tumors | completed | N/A | 38 | Mercy ResearchOTHER | 1 | Jun 18, 2020 | clinicaltrials |
| NCT00727233 | Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | completed | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT00076102 | Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2018 | clinicaltrials |
Data updated 7 hours agoSource updated Sep 29, 2026source: clinicaltrials